SWOG clinical trial number
CTSU/E1697

Phase III Randomized Study of Four Weeks of High Dose IFN-alpha2b in Stage T2b N0, T3a-b N0, T4a-b N0, and T1-4, N1a, 2a, 3(Microscopic) Melanoma

Closed
Phase
Published
Abbreviated Title
High Dose IFN-alpha 2b Stage T3-T4 or N1 Melanoma
Activated
10/15/2002
Closed
10/27/2010
Participants
CTSU

Research committees

Melanoma

Treatment

Surgery Interferon alpha-2b

Eligibility Criteria Expand/Collapse

The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.

Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for more information and registration procedures.

Publication Information Expand/Collapse

2017

Phase III randomized study of 4 weeks of high-dose interferon-a-2b in stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) melanoma: a trial of the Eastern Cooperative Oncology Group–American College of Radiology Imaging Network Cancer Research Group (E1697)

S Agarwala;SJ Lee;W Yip;U Rao;A Tarhini;G Cohen;D Reintgen;T Evans;J Brell;M Albertini;M Atkins;S Dakhil;R Conry;JA Sosman;L Flaherty;V Sondak;WE Carson;M Smylie;A Pappo;R Kefford;J Kirkwood Journal of Clinical Oncology Mar 10;35(8):885-892

PMid: PMID28135150 | PMC number: PMC5455684

2011

Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate and high-risk melanoma (Intergroup trial E 1697)

A Agarwala;SJ Lee;LE Flaherty;M Smylie;RF Kefford;WE Carson;G Cohen;JM Kirkwood Journal of Clinical Oncology Vol 29, No 15_suppl (May 20 Supplement), 2011: abst. 8505; ASCO Annual Meeting ((June 4-8, 2011, Chicago, IL), oral;

2008

Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for?

VK Sondak;LE Flaherty Lancet 372:89-90

PMid: PMID18620932

Other Clinical Trials

SWOG Clinical Trial Number
S2000

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases
Research Committee(s)
Melanoma
Activated
09/23/2020
Accrual
100%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6174

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Research Committee(s)
Melanoma
Activated
10/01/2018
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6141

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Research Committee(s)
Melanoma
Activated
09/10/2015
Open
Phase